Published in Neuroimage on December 18, 2006
Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab (2009) 1.80
Hyperstimulation of striatal D2 receptors with sleep deprivation: Implications for cognitive impairment. Neuroimage (2009) 1.04
Neurovascular coupling to D2/D3 dopamine receptor occupancy using simultaneous PET/functional MRI. Proc Natl Acad Sci U S A (2013) 1.02
Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine. Psychopharmacology (Berl) (2010) 0.96
Estimating neurotransmitter kinetics with ntPET: a simulation study of temporal precision and effects of biased data. Neuroimage (2007) 0.94
Occupancy of dopamine D2/3 receptors in rat brain by endogenous dopamine measured with the agonist positron emission tomography radioligand [11C]MNPA. Synapse (2008) 0.90
The applicability of SRTM in [(18)F]fallypride PET investigations: impact of scan durations. J Cereb Blood Flow Metab (2011) 0.89
Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders. J Biomed Biotechnol (2012) 0.87
Kinetic brain analysis and whole-body imaging in monkey of [11C]MNPA: a dopamine agonist radioligand. Synapse (2008) 0.80
Cocaine cue-induced dopamine release in the human prefrontal cortex. J Psychiatry Neurosci (2016) 0.78
18F-fallypride binding potential in patients with schizophrenia compared to healthy controls. Schizophr Res (2010) 0.76
Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology. Int J Neuropsychopharmacol (2016) 0.75
Testing for radioligand sensitivity to endogenous neurotransmitter release. Eur J Nucl Med Mol Imaging (2009) 0.75
Design of Infusion Schemes for Neuroreceptor Imaging: Application to [(11)C]Flumazenil-PET Steady-State Study. Biomed Res Int (2016) 0.75
Recent progress of imaging agents for Parkinson's disease. Curr Neuropharmacol (2014) 0.75
Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab (2007) 11.79
MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. Neuroimage (2004) 2.07
Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry (2009) 1.71
Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol (2010) 1.67
Schizophrenia: from the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World J Biol Psychiatry (2009) 1.64
Evaluation of the Serotonin Transporter Ligand 123I-ADAM for SPECT Studies on Humans. J Nucl Med (2008) 1.60
Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab Dispos (2008) 1.50
Exploring regional variation in antipsychotic coprescribing practice: a Danish questionnaire survey. J Clin Psychiatry (2010) 1.43
Measurements of brain-derived neurotrophic factor: methodological aspects and demographical data. Brain Res Bull (2007) 1.35
The relationship between cerebral blood flow and volume in humans. Neuroimage (2005) 1.29
Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT (2A) agonist PET tracers. Eur J Nucl Med Mol Imaging (2010) 1.27
Cognitive and functional neuroimaging correlate for anosognosia in mild cognitive impairment and Alzheimer's disease. Int J Geriatr Psychiatry (2005) 1.21
European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging (2012) 1.19
Measuring endogenous 5-HT release by emission tomography: promises and pitfalls. J Cereb Blood Flow Metab (2010) 1.16
Frontolimbic serotonin 2A receptor binding in healthy subjects is associated with personality risk factors for affective disorder. Biol Psychiatry (2007) 1.15
Cluster analysis in kinetic modelling of the brain: a noninvasive alternative to arterial sampling. Neuroimage (2004) 1.14
Hemodynamic and neuroendocrine responses to changes in sodium intake in compensated heart failure. Am J Physiol Regul Integr Comp Physiol (2005) 1.12
Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug. Psychiatry Res (2007) 1.11
5-HT radioligands for human brain imaging with PET and SPECT. Med Res Rev (2011) 1.10
Effects of antipsychotics on prepulse inhibition of the startle response in drug-naïve schizophrenic patients. Biol Psychiatry (2002) 1.08
The 5-HT1A serotonin receptor is located on calbindin- and parvalbumin-containing neurons in the rat brain. Brain Res (2003) 1.08
Development of a (11)C-labeled tetrazine for rapid tetrazine-trans-cyclooctene ligation. Chem Commun (Camb) (2013) 1.08
Depression and Alzheimer's disease: is stress the initiating factor in a common neuropathological cascade? J Alzheimers Dis (2011) 1.04
Hippocampal and caudate volume reductions in antipsychotic-naive first-episode schizophrenia. J Psychiatry Neurosci (2010) 1.03
A database of [(18)F]-altanserin binding to 5-HT(2A) receptors in normal volunteers: normative data and relationship to physiological and demographic variables. Neuroimage (2004) 1.03
Neurovascular coupling to D2/D3 dopamine receptor occupancy using simultaneous PET/functional MRI. Proc Natl Acad Sci U S A (2013) 1.02
Seasonal changes in brain serotonin transporter binding in short serotonin transporter linked polymorphic region-allele carriers but not in long-allele homozygotes. Biol Psychiatry (2010) 1.00
Drug-induced mild therapeutic hypothermia obtained by administration of a transient receptor potential vanilloid type 1 agonist. BMC Cardiovasc Disord (2010) 0.99
α4βδ GABA(A) receptors are high-affinity targets for γ-hydroxybutyric acid (GHB). Proc Natl Acad Sci U S A (2012) 0.99
Brain imaging of serotonin 4 receptors in humans with [11C]SB207145-PET. Neuroimage (2010) 0.98
Decreased frontal serotonin2A receptor binding in antipsychotic-naive patients with first-episode schizophrenia. Arch Gen Psychiatry (2010) 0.98
"Central command" and insular activation during attempted foot lifting in paraplegic humans. Hum Brain Mapp (2005) 0.98
Laser Doppler flowmetry is valid for measurement of cerebral blood flow autoregulation lower limit in rats. Exp Physiol (2005) 0.98
Quantification of 5-HT2A receptors in the human brain using [18F]altanserin-PET and the bolus/infusion approach. J Cereb Blood Flow Metab (2003) 0.98
The relationship of needs and quality of life in persons with schizophrenia living in the community. A Nordic multi-center study. Nord J Psychiatry (2003) 0.97
Dopa-responsive dystonia and early-onset Parkinson's disease in a patient with GTP cyclohydrolase I deficiency? Mov Disord (2006) 0.96
Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine. Psychopharmacology (Berl) (2010) 0.96
An incomplete TCA cycle increases survival of Salmonella Typhimurium during infection of resting and activated murine macrophages. PLoS One (2010) 0.96
Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei. Int J Neuropsychopharmacol (2005) 0.95
The brain 5-HT4 receptor binding is down-regulated in the Flinders Sensitive Line depression model and in response to paroxetine administration. J Neurochem (2009) 0.95
Source localization of sensory gating: a combined EEG and fMRI study in healthy volunteers. Neuroimage (2010) 0.95
Cognitive testing of pigs (Sus scrofa) in translational biobehavioral research. Neurosci Biobehav Rev (2010) 0.94
Progressive striatal and hippocampal volume loss in initially antipsychotic-naive, first-episode schizophrenia patients treated with quetiapine: relationship to dose and symptoms. Int J Neuropsychopharmacol (2010) 0.94
The personality trait openness is related to cerebral 5-HTT levels. Neuroimage (2008) 0.94
Mass dose effects and in vivo affinity in brain PET receptor studies--a study of cerebral 5-HT4 receptor binding with [11C]SB207145. Nucl Med Biol (2011) 0.94
Sensorimotor gating and habituation in antipsychotic-naive, first-episode schizophrenia patients before and after 6 months' treatment with quetiapine. Int J Neuropsychopharmacol (2010) 0.93
Missense dopamine transporter mutations associate with adult parkinsonism and ADHD. J Clin Invest (2014) 0.92
Kinetic modeling of 11C-SB207145 binding to 5-HT4 receptors in the human brain in vivo. J Nucl Med (2009) 0.92
Frontal dopamine D(2/3) receptor binding in drug-naive first-episode schizophrenic patients correlates with positive psychotic symptoms and gender. Biol Psychiatry (2006) 0.92
The BDNF Val66Met polymorphism: relation to familiar risk of affective disorder, BDNF levels and salivary cortisol. Psychoneuroendocrinology (2009) 0.91
Changes in BOLD and ADC weighted imaging in acute hypoxia during sea-level and altitude adapted states. Neuroimage (2005) 0.90
Serotonin 2A receptors contribute to the regulation of risk-averse decisions. Neuroimage (2013) 0.90
11C-NS14492 as a novel PET radioligand for imaging cerebral alpha7 nicotinic acetylcholine receptors: in vivo evaluation and drug occupancy measurements. J Nucl Med (2011) 0.89
Playing it safe but losing anyway--serotonergic signaling of negative outcomes in dorsomedial prefrontal cortex in the context of risk-aversion. Eur Neuropsychopharmacol (2012) 0.89
No change in [¹¹C]CUMI-101 binding to 5-HT(1A) receptors after intravenous citalopram in human. Synapse (2012) 0.89
[18F]altanserin binding to human 5HT2A receptors is unaltered after citalopram and pindolol challenge. J Cereb Blood Flow Metab (2004) 0.89
Cerebral hemodynamics measured with simultaneous PET and near-infrared spectroscopy in humans. Brain Res (2002) 0.89
No association between striatal dopamine transporter binding and body mass index: a multi-center European study in healthy volunteers. Neuroimage (2012) 0.89
Serotonin 2A receptors, citalopram and tryptophan-depletion: a multimodal imaging study of their interactions during response inhibition. Neuropsychopharmacology (2012) 0.88
Characterization of [(11)C]Cimbi-36 as an agonist PET radioligand for the 5-HT(2A) and 5-HT(2C) receptors in the nonhuman primate brain. Neuroimage (2013) 0.88
Hippocampal volume changes in healthy subjects at risk of unipolar depression. J Psychiatr Res (2010) 0.87
Immunodetection of the serotonin transporter protein is a more valid marker for serotonergic fibers than serotonin. Synapse (2006) 0.87
Gene variations in the cholecystokinin system in patients with panic disorder. Psychiatr Genet (2010) 0.87
In vivo imaging of cerebral serotonin transporter and serotonin(2A) receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") and hallucinogen users. Arch Gen Psychiatry (2011) 0.87
Evaluation of the novel 5-HT4 receptor PET ligand [11C]SB207145 in the Göttingen minipig. J Cereb Blood Flow Metab (2008) 0.87
Severe and rapidly progressing cognitive phenotype in a SCA17-family with only marginally expanded CAG/CAA repeats in the TATA-box binding protein gene: a case report. BMC Neurol (2012) 0.87
Cerebral blood flow autoregulation in early experimental S. pneumoniae meningitis. J Appl Physiol (1985) (2006) 0.87
Loss of serotonin 2A receptors exceeds loss of serotonergic projections in early Alzheimer's disease: a combined [11C]DASB and [18F]altanserin-PET study. Neurobiol Aging (2010) 0.86
Lack of association between prior depressive episodes and cerebral [11C]PiB binding. Neurobiol Aging (2011) 0.86
Whole blood BDNF levels in healthy twins discordant for affective disorder: association to life events and neuroticism. J Affect Disord (2007) 0.85
The effects of imipramine on P50 suppression, prepulse inhibition and habituation of the startle response in humans. Int J Neuropsychopharmacol (2007) 0.85
Impaired temporoparietal deactivation with working memory load in antipsychotic-naïve patients with first-episode schizophrenia. World J Biol Psychiatry (2011) 0.85
Serotonin 2A receptor antagonists for treatment of schizophrenia. Expert Opin Investig Drugs (2011) 0.85
Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first-episode drug-naive schizophrenic patients. CNS Spectr (2004) 0.85
Age and sex effects on 5-HT(4) receptors in the human brain: a [(11)C]SB207145 PET study. J Cereb Blood Flow Metab (2011) 0.85
5-HTTLPR status predictive of neocortical 5-HT4 binding assessed with [(11)C]SB207145 PET in humans. Neuroimage (2012) 0.85
Cognitive effects of six months of treatment with quetiapine in antipsychotic-naïve first-episode schizophrenia. Psychiatry Res (2010) 0.85
Increased urinary orosomucoid excretion is not related to impaired renal function in patients with type 2 diabetes. J Diabetes Complications (2008) 0.84
Quantification of 123I-PE2I binding to dopamine transporter with SPECT after bolus and bolus/infusion. J Nucl Med (2005) 0.84
High familial risk for mood disorder is associated with low dorsolateral prefrontal cortex serotonin transporter binding. Neuroimage (2009) 0.84
Longitudinal assessment of cerebral 5-HT2A receptors in healthy elderly volunteers: an [18F]-altanserin PET study. Eur J Nucl Med Mol Imaging (2008) 0.84
Extrastriatal binding of [¹²³I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls. Eur J Nucl Med Mol Imaging (2014) 0.84
The effect of S. pneumoniae bacteremia on cerebral blood flow autoregulation in rats. J Cereb Blood Flow Metab (2007) 0.84
Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia: a randomized clinical trial - the SMART trial protocol. BMC Psychiatry (2011) 0.84
Neuroimaging of the serotonin reuptake site requires high-affinity ligands. Synapse (2007) 0.84
Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder. Trials (2010) 0.84
Radiosynthesis and evaluation of 11C-CIMBI-5 as a 5-HT2A receptor agonist radioligand for PET. J Nucl Med (2010) 0.84
Cocaine is pharmacologically active in the nonhuman primate fetal brain. Proc Natl Acad Sci U S A (2010) 0.84
The 5-HT2A receptor binding pattern in the human brain is strongly genetically determined. Neuroimage (2007) 0.83
Reproducibility of 5-HT2A receptor measurements and sample size estimations with [18F]altanserin PET using a bolus/infusion approach. Eur J Nucl Med Mol Imaging (2006) 0.83
Cerebral pressure autoregulation and vasoreactivity in the newborn rat. Pediatr Res (2004) 0.83
Binding characteristics of the 5-HT2A receptor antagonists altanserin and MDL 100907. Synapse (2005) 0.83
Activation of glucocorticoid receptors increases 5-HT2A receptor levels. Exp Neurol (2009) 0.83
Increased susceptibility to cardiovascular effects of dihydrocapcaicin in resuscitated rats. Cardiovascular effects of dihydrocapsaicin. BMC Cardiovasc Disord (2010) 0.83